Joseph Tumang

Joseph Tumang, Ph.D., joins Sigilon as VP, Head of Immune Mediated Diseases. Previously, Dr. Tumang was Director of the Cancer Immunology department at Boehringer-Ingelheim, where he led the in vitro, the in vivo, and most recently the oncology translational sciences teams. Prior to this, he led drug discovery projects at EMD Serono, Pfizer, and Compass Therapeutics. Dr. Tumang graduated from Cornell University as a card-carrying immunologist and has published papers on both autoimmune diseases and cancer immunology.